Chinese herbal medicines for treating ulcerative colitis via regulating gut microbiota-intestinal immunity axis

Yang, Yifei; Wang, Yi; Zhao, L.; Wang, Fang; Li, Mingxing; Wang, Qin; Luo, Haoming; Zhao, Qianyun; Zeng, Jiuping; Zhao, Yueshui; Du, Fukuan; Chen, Yu; Shen, Jing; Wei, Shulin; Xiao, Zhangang; Wu, Xu

doi:10.1016/j.chmed.2023.03.003

Cited by 27 publications

(14 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, due to its intricate composition of TCMs, elucidating their specific functional mechanisms remains challenging. Prosperous research on the gut microbiome over the past two decades has opened up a new vision to explicate the beneficial effects of TCMs on human health (Yang, Wang, Zhao, et al, 2023). An increasing number of studies have revealed a tight connection between certain medicines that improve glucose and lipid metabolism and the upregulation of Akkermansia in the gut.…”

Section: Edible Herb and Their Active Components Regulate A Muciniphi...mentioning

confidence: 99%

Therapeutic potential of dietary nutrients and medicinal foods against metabolic disorders: Targeting Akkermansia muciniphila

Xu,

Zhang,

Yang

et al. 2024

Food Frontiers

View full text Add to dashboard Cite

As one of the most attractive next‐generation probiotics, mucin‐degrading Akkermansia muciniphila has emerged as an essential and integral factor in maintaining human health and affecting pathological outcomes. Its abundance is inversely associated with various metabolic diseases (e.g., obesity and type 2 diabetes), cardiovascular diseases, and intestinal inflammation. Supplementing A. muciniphila to restore the gut microbiota ecosystem is a promising approach for treating metabolic disorders. However, the direct utilization of this probiotic is limited by technological and regulatory hurdles, such as the in vitro bulk culture of A. muciniphila and the need for expensive animal‐derived materials. Therefore, enrichment of A. muciniphila using nutraceutical supplements is a feasible strategy. Dietary supplements, especially medicinal herbs, offer a vast and valuable resource as potential prebiotics for promoting the growth of A. muciniphila in the gut, ensuring reliable safety and efficacy. In this study, we first systemically reviewed the dietary substances and medicinal foods known to promote A. muciniphila from over 100 literature sources, aiming to establish a candidate basis for future exploration of prebiotics targeting A. muciniphila. Furthermore, we summarized and discussed the major regulatory factors and mechanisms responsible for the beneficial effect of A. muciniphila on metabolic disorders, hoping to open up exciting directions for in‐depth research on the pharmacological mechanism of A. muciniphila and pave the way for its clinical therapeutics.

show abstract

Section: Edible Herb and Their Active Components Regulate A Muciniphi...mentioning

confidence: 99%

Therapeutic potential of dietary nutrients and medicinal foods against metabolic disorders: Targeting Akkermansia muciniphila

Xu,

Zhang,

Yang

et al. 2024

Food Frontiers

View full text Add to dashboard Cite

show abstract

“…Recently, growing evidence has shown that an imbalance of the intestinal flora is a critical pathogenic factor in colitis [21]. To elucidate whether the beneficial effects of RT4 on colitis are related to the regulation of intestinal microbiota, we collected fresh feces from the mice and performed 16S rRNA sequencing detection.…”

Section: Rt4 Modulated the Composition Of Gut Microbiotamentioning

confidence: 99%

Study on the Anti-Ulcerative Colitis Effect of Pseudo-Ginsenoside RT4 Based on Gut Microbiota, Pharmacokinetics, and Tissue Distribution

Yu,

Wang,

et al. 2024

IJMS

View full text Add to dashboard Cite

The purpose of this study was to explore the therapeutic effect of the oral administration of pseudo-ginsenoside RT4 (RT4) on ulcerative colitis (UC), and to determine the rate of absorption and distribution of RT4 in mice with UC. Balb/c mice were induced using dextran sulfate sodium salts (DSS) to establish the UC model, and 10, 20, or 40 mg/kg of RT4 was subsequently administered via gavage. The clinical symptoms, inflammatory response, intestinal barrier, content of total short-chain fatty acids (SCFAs), and gut microbiota were investigated. Caco-2 cells were induced to establish the epithelial barrier damage model using LPS, and an intervention was performed using 4, 8, and 16 µg/mL of RT4. The inflammatory factors, transient electrical resistance (TEER), and tight-junction protein expression were determined. Finally, pharmacokinetic and tissue distribution studies following the intragastric administration of RT4 in UC mice were performed. According to the results in mice, RT4 decreased the disease activity index (DAI) score, restored the colon length, reduced the levels of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β), and boosted the levels of immunosuppressive cytokine IL-10, increased the content of SCFAs, improved the colonic histopathology, maintained the ultrastructure of colonic mucosal epithelial cells, and corrected disturbances in the intestinal microbiota. Based on the results in caco-2 cells, RT4 reduced the levels of TNF-α, IL-6, and IL-1β; protected integrity of monolayers; and increased tight-junction protein expression. Additionally, the main pharmacokinetic parameters (Cmax, Tmax, t1/2, Vd, CL, AUC) were obtained, the absolute bioavailability was calculated as 18.90% ± 2.70%, and the main distribution tissues were the small intestine and colon. In conclusion, RT4, with the features of slow elimination and directional distribution, could alleviate UC by inhibiting inflammatory factors, repairing the intestinal mucosal barrier, boosting the dominant intestinal microflora, and modulating the expression of SCFAs.

show abstract

“…In the realm of research and education, the pursuit of herbal interventions for IBD unfolds against a backdrop of knowledge gaps, methodological challenges, and regulatory ambiguities. High-quality evidence from well-designed clinical trials remains sparse, underscoring the need for further research to establish the safety and efficacy of herbal interventions definitively [64]. Provider education emerges as a cornerstone of successful integration, with healthcare professionals requiring comprehensive training and continuing education to navigate the complexities of herbal medicine effectively [65].…”

Section: Exploring Novel Herbal Compounds and Formulations For Inflam...mentioning

confidence: 99%

Exploring Novel Herbal Compounds and Formulations for Inflammatory Bowel Disease (IBD) Management

Dubey,

Shukla

2023

CJAP

View full text Add to dashboard Cite

Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, presents a complex and challenging clinical scenario characterized by chronic inflammation of the gastrointestinal tract. Traditional herbal medicine has garnered increasing interest as a potential adjunctive or alternative therapy for IBD, owing to its perceived efficacy, safety profile, and holistic approach to health. This review provides a comprehensive overview of the current landscape of herbal interventions for IBD, addressing scientific, regulatory, clinical, and patient-related considerations. Scientifically, the exploration of herbal interventions faces challenges related to the complexity of herbal formulations, standardization, and quality control. Regulatory hurdles encompass stringent requirements for safety, efficacy, and quality standards, necessitating adherence to robust preclinical and clinical protocols. Clinically, the heterogeneity of the patient population, potential interactions with conventional therapies, and patient preferences pose challenges in the integration of herbal interventions into clinical practice.

show abstract

Chinese herbal medicines for treating ulcerative colitis via regulating gut microbiota-intestinal immunity axis

Cited by 27 publications

References 125 publications

Therapeutic potential of dietary nutrients and medicinal foods against metabolic disorders: Targeting Akkermansia muciniphila

Therapeutic potential of dietary nutrients and medicinal foods against metabolic disorders: Targeting Akkermansia muciniphila

Study on the Anti-Ulcerative Colitis Effect of Pseudo-Ginsenoside RT4 Based on Gut Microbiota, Pharmacokinetics, and Tissue Distribution

Exploring Novel Herbal Compounds and Formulations for Inflammatory Bowel Disease (IBD) Management

Contact Info

Product

Resources

About